Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2020

13.09.2019 | Correspondence

Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema

verfasst von: Sumeet P. Mirgh, Rayaz Ahmed, Narendra Agrawal, Sneha Bothra, Bhaarat Mohan, Ambar Garg, Shinto Francis Thekkudan, Vishvdeep Khushoo, Dinesh Bhurani

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs 73:789–802PubMedCrossRef Makri OE, Georgalas I, Georgakopoulos CD (2013) Drug-induced macular edema. Drugs 73:789–802PubMedCrossRef
2.
Zurück zum Zitat Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844 Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844
3.
Zurück zum Zitat Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176PubMedCrossRef Farooqui MZH, Valdez J, Martyr S et al (2015) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16:169–176PubMedCrossRef
4.
Zurück zum Zitat Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698PubMedPubMedCentralCrossRef Bernard S, Goldwirt L, Amorim S et al (2015) Activity of ibrutinib in mantle cell lymphoma patients with central nervous systemrelapse. Blood 126:1695–1698PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223PubMedPubMedCentralCrossRef Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia. N Engl J Med 371:213–223PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707 Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707
Metadaten
Titel
Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema
verfasst von
Sumeet P. Mirgh
Rayaz Ahmed
Narendra Agrawal
Sneha Bothra
Bhaarat Mohan
Ambar Garg
Shinto Francis Thekkudan
Vishvdeep Khushoo
Dinesh Bhurani
Publikationsdatum
13.09.2019
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2020
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-019-01181-y

Weitere Artikel der Ausgabe 1/2020

Indian Journal of Hematology and Blood Transfusion 1/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.